Morgan Stanley Analysts Give Merck KGaA (MRK) a €90.00 Price Target

Morgan Stanley set a €90.00 ($104.65) price target on Merck KGaA (FRA:MRK) in a research note released on Monday morning. The firm currently has a neutral rating on the healthcare company’s stock.

MRK has been the topic of a number of other reports. Sanford C. Bernstein set a €105.00 ($122.09) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, January 3rd. Commerzbank set a €100.00 ($116.28) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, November 8th. Barclays set a €78.00 ($90.70) price target on Merck KGaA and gave the company a sell rating in a report on Tuesday, January 15th. Credit Suisse Group set a €93.00 ($108.14) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday, October 23rd. Finally, JPMorgan Chase & Co. set a €95.00 ($110.47) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. Merck KGaA currently has an average rating of Hold and a consensus price target of €98.80 ($114.88).

Shares of Merck KGaA stock opened at €96.44 ($112.14) on Monday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: Reverse Stock Split

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply